Chan Y. Cheah

9.3k total citations · 2 hit papers
196 papers, 3.5k citations indexed

About

Chan Y. Cheah is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Chan Y. Cheah has authored 196 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 101 papers in Genetics and 89 papers in Oncology. Recurrent topics in Chan Y. Cheah's work include Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (90 papers) and CAR-T cell therapy research (41 papers). Chan Y. Cheah is often cited by papers focused on Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (90 papers) and CAR-T cell therapy research (41 papers). Chan Y. Cheah collaborates with scholars based in Australia, United States and United Kingdom. Chan Y. Cheah's co-authors include John F. Seymour, Nathan Fowler, Michael Wang, Andrew Wirth, Katharine L. Lewis, Toby A. Eyre, Tarec Christoffer El‐Galaly, H. Miles Prince, Loretta J. Nastoupil and Dai Chihara and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Chan Y. Cheah

169 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. profile →
Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review

2022 124 citations Chan Y. Cheah et al. profile →

Peers

Countries citing papers authored by Chan Y. Cheah

Since Specialization

Citations

This map shows the geographic impact of Chan Y. Cheah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chan Y. Cheah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chan Y. Cheah more than expected).

Fields of papers citing papers by Chan Y. Cheah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chan Y. Cheah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chan Y. Cheah. The network helps show where Chan Y. Cheah may publish in the future.

Co-authorship network of co-authors of Chan Y. Cheah

This figure shows the co-authorship network connecting the top 25 collaborators of Chan Y. Cheah. A scholar is included among the top collaborators of Chan Y. Cheah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chan Y. Cheah. Chan Y. Cheah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study	Blood	Constantine S. Tam, Anna Maria Frustaci et al.	2
2	CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies	Blood	Armin Ghobadi, Joseph P. McGuirk et al.	5
3	Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).	Journal of Clinical Oncology	Yasmin Karimi, Catherine Thiéblemont et al.	5
4	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study	Journal of Clinical Oncology	Lihua E. Budde, Sarit Assouline et al.	34
5	Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance	Internal Medicine Journal	Joshua W.D. Tobin, Greg Hapgood et al.	2
6	Marginal zone lymphoma: 2023 update on diagnosis and management	American Journal of Hematology	Chan Y. Cheah, John F. Seymour	15
7	CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies	Clinical Lymphoma Myeloma & Leukemia	Catherine E. Muehlenbein, Catherine C. Coombs et al.	1
8	A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma	Clinical Epigenetics	Jake Shortt, Peter Galettis et al.	3
9	How I manage mantle cell lymphoma: indolent versus aggressive disease	British Journal of Haematology	Matthew R. Wilson, Chan Y. Cheah et al.	6
10	Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom	British Journal of Haematology	Adrian Minson, Nada Hamad et al.	3
11	Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma	Blood Advances	Diego Villa, Aixiang Jiang et al.	11
12	Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance	British Journal of Haematology	Mark N. Polizzotto, Sam Milliken et al.	4
13	Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?	British Journal of Haematology	Tarec Christoffer El‐Galaly, Diego Villa et al.	17
14	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies	Blood	Elizabeth Budde, Ajay K. Gopal et al.	22
15	TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma	HemaSphere	Chan Y. Cheah, Wojciech Jurczak et al.	1
16	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts	Blood	Matthew J. Matasar, Chan Y. Cheah et al.	27
17	Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance	Leukemia & lymphoma	Xuan Tan, Chan Y. Cheah et al.	0
18	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls	British Journal of Haematology	Tarec Christoffer El‐Galaly, Chan Y. Cheah et al.	5
19	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study	Blood Advances	Allison Barraclough, Musa Alzahrani et al.	28
20	Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study	Blood	Allison Barraclough, Musa Alzahrani et al.	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact